Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

February newsletter Julia’s insights

Julia Lee
February 24, 2017

CEO interview – Cobalt Blue

Bell Direct
February 21, 2017

Your Money Your Call

Julia Lee
February 14, 2017

Your Money Your Call

Julia Lee
February 7, 2017

January review

Julia Lee
January 27, 2017

Superannuation Reforms

Bell Direct
January 16, 2017

Market Update

Julia Lee
January 16, 2017

Market Update

Julia Lee
January 13, 2017

Market Update 12 Jan

Julia Lee
January 12, 2017